Design, synthesis and antimycobacterial activity of novel imidazo[1,2-a]pyridine-3-carboxamide derivatives. 2017

Kai Lv, and Linhu Li, and Bo Wang, and Mingliang Liu, and Bin Wang, and Weiyi Shen, and Huiyuan Guo, and Yu Lu
Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.

We report herein the design and synthesis of "novel imidazo [1,2-a]pyridine-3-carboxamides (IPAs)" bearing a variety of different linkers, based on the structure of IMB-1402 discovered in our lab. Results reveal that 2,6-dimethyl-N-[2-(phenylamino)ethyl] IPAs with an electron-donating group on the benzene ring as a potent scaffold. Compounds 26g and 26h have considerable activity (MIC: 0.041-2.64 μM) against drug-sensitive/resistant MTB strains, and they have acceptable safety indices against MTB H37Rv with the SI values of 4395 and 1405, respectively. Moreover, N-[2-(piperazin-1-yl)ethyl] moiety was also identified as a potentially alternative linker (compound 31), opening a new direction for further SAR studies.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

Kai Lv, and Linhu Li, and Bo Wang, and Mingliang Liu, and Bin Wang, and Weiyi Shen, and Huiyuan Guo, and Yu Lu
December 2015, Molecules (Basel, Switzerland),
Kai Lv, and Linhu Li, and Bo Wang, and Mingliang Liu, and Bin Wang, and Weiyi Shen, and Huiyuan Guo, and Yu Lu
March 2019, European journal of medicinal chemistry,
Kai Lv, and Linhu Li, and Bo Wang, and Mingliang Liu, and Bin Wang, and Weiyi Shen, and Huiyuan Guo, and Yu Lu
October 2009, European journal of medicinal chemistry,
Kai Lv, and Linhu Li, and Bo Wang, and Mingliang Liu, and Bin Wang, and Weiyi Shen, and Huiyuan Guo, and Yu Lu
August 2021, Toxicology in vitro : an international journal published in association with BIBRA,
Kai Lv, and Linhu Li, and Bo Wang, and Mingliang Liu, and Bin Wang, and Weiyi Shen, and Huiyuan Guo, and Yu Lu
January 2016, European journal of medicinal chemistry,
Kai Lv, and Linhu Li, and Bo Wang, and Mingliang Liu, and Bin Wang, and Weiyi Shen, and Huiyuan Guo, and Yu Lu
December 2020, Bioorganic & medicinal chemistry,
Kai Lv, and Linhu Li, and Bo Wang, and Mingliang Liu, and Bin Wang, and Weiyi Shen, and Huiyuan Guo, and Yu Lu
September 2013, Bioorganic & medicinal chemistry letters,
Kai Lv, and Linhu Li, and Bo Wang, and Mingliang Liu, and Bin Wang, and Weiyi Shen, and Huiyuan Guo, and Yu Lu
October 2015, Chemical biology & drug design,
Kai Lv, and Linhu Li, and Bo Wang, and Mingliang Liu, and Bin Wang, and Weiyi Shen, and Huiyuan Guo, and Yu Lu
December 2023, RSC advances,
Kai Lv, and Linhu Li, and Bo Wang, and Mingliang Liu, and Bin Wang, and Weiyi Shen, and Huiyuan Guo, and Yu Lu
January 2015, European journal of medicinal chemistry,
Copied contents to your clipboard!